PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
17.97%
Revenue growth of 17.97% vs. zero growth in Healthcare. Walter Schloss might still want to see if it can translate into profits.
-9.53%
Negative gross profit growth while Healthcare median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-37.46%
Negative EBIT growth while Healthcare median is -4.60%. Seth Klarman would check if external or internal factors caused the decline.
-37.46%
Negative operating income growth while Healthcare median is -5.59%. Seth Klarman would check if structural or cyclical issues are at play.
111.86%
Positive net income growth while Healthcare median is negative. Peter Lynch would view this as a notable competitive advantage.
116.82%
Positive EPS growth while Healthcare median is negative. Peter Lynch might see a strong advantage in per-share earnings compared to peers.
116.82%
Positive diluted EPS growth while Healthcare median is negative. Peter Lynch might see a real advantage in how this firm manages share count or drives net income.
68.21%
Share change of 68.21% while Healthcare median is zero. Walter Schloss would see if the modest difference matters long-term.
68.21%
Diluted share change of 68.21% while Healthcare median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
9996.05%
OCF growth of 9996.05% while Healthcare is zero. Walter Schloss might see a modest positive difference, which can compound over time.
105.91%
FCF growth of 105.91% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
759.81%
5Y CAGR of 759.81% while Healthcare is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
558.89%
3Y CAGR of 558.89% while Healthcare median is zero. Walter Schloss might see a modest improvement overshadowing the broader sector’s stagnation.
1314.74%
OCF/share CAGR of 1314.74% while Healthcare median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
272.75%
OCF/share CAGR of 272.75% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
153.74%
3Y OCF/share growth of 153.74% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
1568.31%
Net income/share CAGR of 1568.31% while Healthcare median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
378.70%
Net income/share CAGR of 378.70% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
445.35%
3Y net income/share CAGR of 445.35% while Healthcare median is zero. Walter Schloss might see a small advantage that can be scaled further.
10037.12%
Equity/share CAGR exceeding 1.5x Healthcare median of 58.81% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
2200.76%
5Y equity/share CAGR > 1.5x Healthcare median of 31.93%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
109.26%
3Y equity/share CAGR > 1.5x Healthcare median of 15.79%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.83%
AR growth of 24.83% while Healthcare median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
-4.14%
Decreasing inventory while Healthcare is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
173.68%
Asset growth of 173.68% while Healthcare median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
115.95%
BV/share growth of 115.95% while Healthcare is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
28.79%
Debt growth of 28.79% while Healthcare median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
188.72%
R&D growth of 188.72% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
-20.02%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.